Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 85,971 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Triple Negative Breast Cancer
Interventions: Trilaciclib, Sacituzumab Govitecan-hziy; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 22
States / cities: Chandler, Arizona • Bakersfield, California • Los Angeles, California + 18 more

Conditions: Colorectal Cancer
Interventions: fluorouracil, irinotecan hydrochloride, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 216
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more

Conditions: Histamine Responsive Allergy Patients
Interventions: Bepreve, Refresh Tears; Drug
Lead sponsor: North Texas Institute for Clinical Trials; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Geriatrics, Drug Therapy, Poly Pharmacy
Interventions: Enhanced Pharmacy Care; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 65 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Chronic Pain, Complex Regional Pain Syndrome, Failed Back Surgery Syndrome
Interventions: Spinal cord stimulator, Implantation of a spinal cord stimulator; Device · Procedure
Lead sponsor: CHU de Quebec-Universite Laval; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Solid Tumors
Interventions: Azacitidine, Valproic Acid, Carboplatin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Epilepsy, Bone Loss, Osteoporosis, Fractures
Interventions: Risedronate, Placebo + Calcium and Vitamin D; Drug
Lead sponsor: Boston VA Research Institute, Inc.; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opioid Dependence, Substance Abuse Disorders, Complex Medical Patients, Primary Care Patients With Chronic Conditions
Interventions: MOUD "Plus" Intervention (treatment as usual + coordinated counseling and referral to community based peer), Treatment As Usual (primary care with low threshold MOUD prescribing); Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Abiraterone Acetate, Bicalutamide, Biospecimen Collection, Computed Tomography Angiography, Leuprolide, Prednisone, Radiation Therapy, Relugolix; Drug · Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, RO5024048; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 18 more

Conditions: Cataract Surgery Anesthesia
Interventions: Arm 1 Cataract Surgery performed with remimazolam as sedative, Arm 2 Cataract Surgery performed with standard of care sedative; Drug
Lead sponsor: Fred E, Shapiro; Other
Eligibility: 55 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral Intravenous Vein Catheter Phlebitis, Intravenous Infection
Interventions: B. Braun 6.35cm 20 gauge ultralong intravenous catheter, BD 5.71 cm 20 gauge Accucath; Device
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Age-Related Macular Degeneration
Interventions: Ranibizumab; Drug
Lead sponsor: Retina Center, Minnesota; Other
Eligibility: 55 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Advanced Solid Cancers
Interventions: BNT329, CA19-9-targeting monoclonal antibody; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Denver, Colorado • Orlando, Florida • Detroit, Michigan + 1 more

Conditions: Erectile Dysfunction
Interventions: Ritonavir, Ketoconazole, Erythomycin, Avanafil; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 21 Years to 45 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Tobacco Smoking Behavior
Interventions: Reduced Nicotine Cigarettes, Reduced ROS/RNS, Control; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Congestive Heart Failure, Ventricular Function, Left
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple Sclerosis
Interventions: Venoplasty, Sham procedure (non-treatment); Procedure
Lead sponsor: Manish Mehta, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Albany, New York

Conditions: Duchenne Muscular Dystrophy
Interventions: Vamorolone, Prednisone, Placebo; Drug · Other
Lead sponsor: ReveraGen BioPharma, Inc.; Industry
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 10
States / cities: Davis, California • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Major Depressive Disorder
Interventions: Intermittent Theta Burst Stimulation (iTBS), Transcranial Alternating Current Stimulation (tACS), Psychotherapy, Sham (Placebo) Transcranial Alternating Current Stimulation (tACS); Device · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Sleep Initiation and Maintenance Disorders
Interventions: Abbreviated cognitive behavioral therapy, Sleep education/sleep hygiene; Behavioral
Lead sponsor: University of Alabama, Tuscaloosa; Other
Eligibility: 18 Years to 24 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Conditions: Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
Interventions: IV Zometa; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Nasolabial Folds
Interventions: Sculptra Aesthetic, Lidocaine HCL; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 22 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Scottsdale, Arizona • Bradenton, Florida • Austin, Texas + 1 more

Conditions: Familial Mediterranean Fever (FMF), Autoinflammation, Periodic Fever, Fever, Genetic Diseases, ROSAH, ALPK1
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 2 Months to 115 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1994
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more

Search by objective public record fields.

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum

The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing

Randomized Controlled Trial of Enhanced Pharmacy Care in Older Veteran Outpatients

Effects of Spinal Cord Stimulation on Sensory Perceptions of Chronic Pain Patients

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

Antiepileptic Drugs and Osteoporotic Prevention Trial

The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Disorder Seen In Primary Care

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Study of Remimazolam for Cataract Surgery

Evaluating the Role of the Guidewire in Peripheral Intravenous Access: A Randomized Controlled Trial of Ultrasound-Guided Catheter Survival

ERG/EOG Study in AMD Patients Treated With Ranibizumab

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil

Switching to Reduced Oxidant or Nicotine Content Cigarettes in Smokers

Validation of the Gated Blood Pool SPECT: ERNA vs 3D Echo

Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients

A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

CARED : A Novel Rapid Treatment Paradigm for Depression

Self-Help Video for Insomnia in College Students

Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma

Extension Study for 43USSA1705

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics